Reference : Le medicament du mois. Femoston Low (0,5 mg d'estradiol plus 2,5 mg de dydrogesterone...
Scientific journals : Article
Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
Human health sciences : Pharmacy, pharmacology & toxicology
Le medicament du mois. Femoston Low (0,5 mg d'estradiol plus 2,5 mg de dydrogesterone) comme traitement hormonal de substitution a la menopause.
[en] Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy
SCHEEN, André mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques]
Gaspard, Ulysse mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Drug Combinations ; Dydrogesterone/pharmacology ; Estradiol/pharmacology ; Estrogen Replacement Therapy ; Female ; Humans
[en] Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea.
Researchers ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
8. SCHEEN Med Femoston (6).pdfPublisher postprint181.62 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.